نتایج جستجو برای: myeloablative

تعداد نتایج: 1963  

Journal: :Transplantation 2014
Marco Mielcarek Anna Yasmine Kirkorian Robert C Hackman Jeremy Price Barry E Storer Brent L Wood Marylene Leboeuf Milena Bogunovic Rainer Storb Yoshihiro Inamoto Mary E Flowers Paul J Martin Matthew Collin Miriam Merad

BACKGROUND Langerhans cells (LCs) are self-renewing epidermal myeloid cells that can migrate and mature into dendritic cells. Recipient LCs that survive cytotoxic therapy given in preparation for allogeneic hematopoietic cell transplantation may prime donor T cells to mediate cutaneous graft-versus-host disease (GVHD). This possible association, however, has not been investigated in the setting...

2015
B. Rajeshkumar P. Agrawal M. Rashighi R. F. Saidi

BACKGROUND Organ transplantation currently requires long-term immunosuppression. This is associated with multiple complications including infection, malignancy and other toxicities. Immunologic tolerance is considered the optimal solution to these limitations. OBJECTIVE To develop a simple and non-toxic regimen to induce mixed chimerism and tolerance using mesenchymal stem cell (MSC) in a mur...

Journal: :Blood 2012
Paul Veys Robert F Wynn Kwang Woo Ahn Sujith Samarasinghe Wensheng He Denise Bonney John Craddock Jacqueline Cornish Stella M Davies Christopher C Dvorak Reggie E Duerst Thomas G Gross Neena Kapoor Carrie Kitko Robert A Krance Wing Leung Victor A Lewis Colin Steward John E Wagner Paul A Carpenter Mary Eapen

To determine whether in vivo T-cell depletion, which lowers GVHD, abrogates the antileukemic benefits of myeloablative total body irradiation-based conditioning and unrelated donor transplantation, in the present study, we analyzed 715 children with acute lymphoblastic leukemia. Patients were grouped for analysis according to whether conditioning included antithymocyte globulin (ATG; n = 191) o...

Journal: :Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation 2016
Nur Soyer Ferit Celik Murat Tombuloglu Fahri Sahin Guray Saydam Filiz Vural

OBJECTIVES The only known curative therapy for primary myelofibrosis is allogeneic hematopoietic stem cell transplant. MATERIALS AND METHODS We retrospectively evaluated 11 transplant procedures involving 10 patients (5 men and 5 women) diagnosed with primary myelofibrosis between 2005 and 2014. RESULTS The median age at the time of transplant was 60.5 years (range, 22-62 years). Stem cell ...

2011
Ri-Young Goh Sung-Hyun Kim Jin-Yeong Han

BACKGROUND Chimerism analysis is an important tool for assessing the origin of hematopoietic cells after allogeneic stem cell transplantation (allo-SCT) and can be used to detect impending graft rejection and the recurrence of underlying malignant or nonmalignant diseases. METHODS This study included 24 patients who underwent myeloablative allo-SCT. DNA was extracted from nucleated cells (NCs...

Journal: :Blood 2007
Françoise Bernaudin Gérard Socie Mathieu Kuentz Sylvie Chevret Michel Duval Yves Bertrand Jean-Pierre Vannier Karima Yakouben Isabelle Thuret Pierre Bordigoni Alain Fischer Patrick Lutz Jean-Louis Stephan Nathalie Dhedin Emmanuel Plouvier Geneviève Margueritte Dominique Bories Suzanne Verlhac Hélène Esperou Lena Coic Jean-Paul Vernant Eliane Gluckman

Allogeneic hematopoietic stem-cell transplantation (HSCT) is the only curative treatment for sickle cell disease (SCD); nevertheless, its use has been limited by the risk of transplantation-related mortality (TRM). Between November 1988 and December 2004, 87 consecutive patients with severe SCD ranging from 2 to 22 years of age received transplants in France. Cerebral vasculopathy was the princ...

2016
M Wilhelm M Smetak P Reimer E Geissinger T Ruediger B Metzner N Schmitz A Engert K Schaefer-Eckart J Birkmann

Current guidelines recommend consolidation with autologous stem cell transplantation (autoSCT) after induction chemotherapy for most patients with peripheral T-cell lymphoma (PTCL). This assumption is based on five prospective phase II studies, three of which included <50 patients with limited follow-up. Here we present the final analysis of the prospective German study. The treatment regimen c...

Journal: :Blood 2011
John Magenau Hiromi Tobai Attaphol Pawarode Thomas Braun Edward Peres Pavan Reddy Carrie Kitko Sung Choi Gregory Yanik David Frame Andrew Harris Harry Erba Lisa Kujawski Kojo Elenitoba-Johnson Jennifer Sanks Dawn Jones Sophie Paczesny James Ferrara John Levine Shin Mineishi

Patients with hematologic malignancies not in remission before allogeneic hematopoietic stem cell transplantation (HSCT) have a poor prognosis. To improve the antitumor activity of conditioning, we combined clofarabine with myeloablative doses of busulfan in a phase 1/2 study in nonremission hematologic malignancies. Forty-six patients were enrolled, including 31 patients with nonremission acut...

2010
Benedetto Bruno Luisa Giaccone Moreno Festuccia Mario Boccadoro

High-dose melphalan with autologous stem cell rescue has been regarded as the standard of care for patients with newly diagnosed myeloma up to the age of 65-70 years. The recent development of agents with potent anti-tumor activity such as thalidomide, lenalidomide and bortezomib has further improved overall survival and response rates. However, relapse is a continuous risk.Allografting is a po...

2012
Adriana Gutiérrez-Hoya Rubén López-Santiago Jorge Vela-Ojeda Laura Montiel-Cervantes Octavio Rodríguez-Cortes Martha Moreno-Lafont

Allogeneic hematopoietic cell transplantation emerges as a therapy option to treat the sequels of exposure to radiation, a great concern at the beginning of the atomic age and cold war (Welniak et al., 2007). Hematopoietic cell transplantation emerged as a rescue strategy since there were already antecedents, like the study of Lorenz et al. in 1952 (as cited by Welniak et al., 2007), who showed...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید